Avidity Biosciences Set to Release Q4 Earnings on February 26

Avidity Biosciences (NASDAQ:RNA) is preparing to release its fourth-quarter earnings for the fiscal year 2025 on February 26, 2026, before the market opens. Analysts anticipate that the company will report a loss of $1.24 per share, along with expected revenue of approximately $1.98 million for the quarter. Investors can expect a conference call to discuss these results at 7:00 AM ET on the same day.

Stock performance has shown some fluctuations as Avidity Biosciences opened at $72.75 on Wednesday. Over the past year, the stock has experienced a low of $21.51 and a high of $73.06. Currently, the company holds a market capitalization of $11.26 billion, with a price-to-earnings ratio of -17.40 and a beta of 0.93. The fifty-day and two-hundred-day simple moving averages stand at $72.52 and $61.75, respectively.

Analyst Ratings and Market Activity

Recent evaluations from various research firms have provided mixed perspectives on Avidity’s stock. On November 11, Chardan Capital maintained a “neutral” rating with a price target of $72.00. Conversely, Wolfe Research downgraded the stock from “strong-buy” to “hold” on October 28. Other firms, such as Evercore and Loop Capital, have also set a target price of $72.00 for the shares.

Currently, the stock has received ratings from eight analysts as a “Buy,” while twelve have assigned a “Hold” rating, and one has recommended a “Sell.” According to MarketBeat.com, the consensus rating is “Hold,” with an average target price of $69.57.

Insider Trading and Institutional Involvement

Recent insider trading activity has seen notable sales from company executives. On January 21, insider Steven George Hughes sold 4,895 shares at an average price of $72.45, totaling approximately $354,642.75. Following this transaction, Hughes retains 31,599 shares valued at around $2.29 million, marking a 13.41% reduction in his ownership.

Additionally, W. Michael Flanagan sold 6,534 shares on the same day, resulting in a total sale of about $473,388.30. After this sale, Flanagan holds 85,093 shares worth approximately $6.16 million, reflecting a 7.13% decrease in his ownership. In total, insiders have sold 58,407 shares valued at around $4.23 million in the past ninety days, with insiders collectively holding 3.83% of the company’s stock.

Institutional investors have also been active, adjusting their positions in Avidity Biosciences. Notable changes include EFG International AG acquiring a new stake in the fourth quarter valued at $33,000. Smartleaf Asset Management LLC significantly increased its holdings by 426.9%, now owning 490 shares worth $35,000. Additional investments were made by Los Angeles Capital Management LLC and Comerica Bank, indicating a growing interest in the company’s potential.

Founded in La Jolla, California, Avidity Biosciences is a clinical-stage biotechnology firm focused on developing antibody-oligonucleotide conjugate (AOC) therapies targeting serious neuromuscular and cardiac diseases. The firm’s proprietary AOC platform aims to enhance delivery mechanisms for RNA-based treatments. Its lead product candidate, AOC 1001, is currently in clinical development for myotonic dystrophy type 1 (DM1), marking a significant step in the application of its innovative platform.

As the company prepares to disclose its earnings, stakeholders will be keen to see how its performance aligns with analyst expectations and market sentiment.